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Although lymphocytes can be specifically activated by cells that express pep-
tide/MHC complexes associated with infection by viruses or bacteria (1), they are
not usually equipped to rapidly eliminate infected target cells . An effective immune
response depends on theelaboration offactors ("lymphokines") that can attract mac-
rophages and other effector cells to the site of infection and enhance their capacity
to destroy ingested microbes (2, 3) . An extensive effort to define such lymphokines
has resulted in the description of a large number of factors in supernatant fluids
of activatedlymphocytesdesignated by acronyms associated with their activity ; MMF
(macrophage migration factor), MIF (migration inhibitory factor), MAF (macro-
phage activation factor), and MCF (macrophage cytotoxicity factor) (4-6) .
To define genes that code for proteins secreted by activated T lymphocytes, we
derived asubset ofcloned cDNA inserts representing genes transcribed shortly after
T cell activation. One such gene, designated Eta-1 (Early T lymphocyte activation
1), 1 encodes a secreted protein which is associated with genetic resistance to in vivo
infection by an obligate intracellular bacteria (7) . Studies of the in vivo expression
ofEta-1 suggested that it might enhance bacterial resistance by affecting the ability
of macrophages to migrate to sites of infection and/or to express bacteriocidal ac-
tivity (7) . We have studied the interaction of the eta-1 protein with macrophages
in vitro and in vivo . We find that purified eta-1 binds specifically to murine macro-
phages through an Arg-Gly-Asp(RGD) containing domainand that in vivo adminis-
tration ofeta-1 results inacellular infiltrate that is composed primarily of this cell type .
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Materials and Methods
Cells.
￿
The mouse myelomonocytic cell line Wehi 3 and fibroblast cell line NIH3T3 were
maintained in DME supplemented with 2 MM L-glutamine, 50 U/ml penicillin, 50 pg/ml
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streptomycin, and 10°Jo heat-inactivated FCS. The generation and culture conditions of the
CD4' T cell clones used in this report, 03, Ar5 and Ar5v, are described elsewhere (8, 9) .
To obtain a cell population enriched for macrophages, peritoneal fluid ofBALB/c mice fol-
lowing intraperitoneal injection of 5 mlPBS was aspirated and 5 x 10 5 cells/ml was incubated
at 37 °C in 96-well tissue culture plates (Flow Laboratories, McLean, VA) . 2 h later nonad-
herent cells were removed after wellswere washed 5-6 times with PBS. Approximately 30-40%
of the cells remained adherent and consisted of95-99% macrophages according to Giemsa
and peroxidase staining and are designated resident peritoneal macrophages (RPM). No Thy-
V cells were detectable by immunofluorescence and 90-95% of the cells were murine Mac-
3' (Boehringer Mannheim, Indianapolis, IN) .
RNA Extraction and Hybridization .
￿
Total RNA was prepared by guanidine isothiocyanate
method as described (7). Aliquots of RNA (20 FAg) were blotted onto nitrocellulose filters
using a Minifold II slot blotter (Schleicher & Schuell, Keene, NH) . The filters were then
baked for 2 h at 80°C in avacuum oven and hybridization of the 32P-radiolabeled probe was
done as described (7). A cDNA probe for Eta-1 has been described previously (7) . TCRce
probe was kindly provided byDr. Anjana Rao (Dana Farber Cancer Institute) and IL-2 probe
by Dr. Brigitte Huber (Tufts Medical School, Boston, MA) .
Preparation ofAr5v Supernatants.
￿
Ar5v cells were maintained inDMEM containing 10%
FCS, 2MM L-glutamine, 501AM2-ME and 1% Con A-depleted spleen conditioned medium
as a source of IL-2 (10) . 1.5 x 10' cells were incubated with 20 ng/ml PMA in the same
medium for 5 h, washed twice withDME and reincubated for an additional 10 h inDMEM
without FCS containing PMA (20 ng/ml) . Supernatants collected at the end of this incuba-
tion were centrifuged at 10,000 g for 20 min before further analysis .
Electrophoresis ofAr5v Supernatants andExtraction ofP65 (eta-1) Proteinfrom Polyacrylamide Gels.
￿
A
modification (7) of the O'Farrell method (11) was used to resolve the supernatant proteins
followed by elution of P65 protein from SDS-polyacrylamide gels . PMA-stimulated Ar5v
supernatants were concentrated 30-40 fold by Centriprep-10 (Amicon Corp., Danvers, MA),
loaded onto isoelectric focusing tube gels and focused for 2.5 h at 400V. After electrophoresis
in the first dimension, the 30-mm piece from the anodic end of the gels corresponding to
pI 4-5 were cut and equilibrated for 20 min in the SDS-sample buffer. Gel slices in sets of
three were loaded onto 10% SDS-polyacrylamide gels for second dimension electrophoresis .
Prestained protein molecular weight markers were loaded before each gel slice . After elec-
trophoresis, one set ofgels was stained and P65 was located in the remaining gels using stained
gel and prestained protein markers . Polyacrylamide gels containing P65 were cut into smaller
pieces, ground, and extracted with 100mM phosphate buffer, pH 7.0, at 37°C for 12 h . Su-
pernatants were microfuged for 15 min to remove gel debris, concentrated, and either dia-
lyzed extensively with phosphate buffer or passed through Extracti Gel-D detergent column
(Pierce Chemical Co., Rockford, IL) to remove traces of SDS. An aliquot of the extracted
protein was re-electrophoresed onto two-dimensional gels to confirm its purity. Protein con-
centration was estimated by the BCA protein assay reagent usingBSA as standard (12) . Ma-
terial for control injections was prepared by isoelectric focusing of sample buffer without pro-
tein followedby electrophoresis under the same conditions as described above for the purification
of P65 protein . Polyacrylamide pieces of these control gels were extracted from the pI 4.5,
65-kD mol mass region of the gel (similar to the location of P65 in the experiment gel) and
processed as described for P65 . P65 and control preparations were tested for the presence
ofendotoxin using Limulus amebocyte lysate (Associates ofCape Cod, Inc., Woods Hole, MA) .
Sequence Analysis.
￿
After concentrated PMA-Ar5v supernatant fluid was electrophoresed
under the conditions described above, proteins were electroblotted on nitrocellulose and stained
with 0.1% Ponceau S (13) . The p65 band was cut from nitrocellulose, subjected to trypsin
digestion, and sequenced on ABI Protein Sequencer Model 477A as described (13) .
Radioiodination of eta-1 (P65).
￿
Iodination of eta-1 (P65) was performed using the Iodo-
bead method (14) . Beads were washed twice with 50mM sodium phosphate buffer, pH 7.4,
and dried on Whatman No . 52 paper. 5 pl of
1251 solution (0.3 mCi/pl ; New England Nu-
clear, Boston, MA) was added to dried beads ; reaction was diluted to 200 Fd with phosphate
buffer and left at room temperature for 5 min. 60 11 of eta-l (0.12 mg/ml) was added to the
preloaded beads and incubated for 15 min atroom temperature. The reaction was quenchedSINGH ET AL.
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by adding 1 Al of freshly prepared 100 mM NaI and labeled protein was separated from the
beads to terminate the reaction. 1251-conjugated eta-1 and free iodine were then separated
over disposable Excellulose desalting columns (Pierce Chemical Co., IL) equilibrated in PBS
containing 0.25% gelatin (ti300 bloom, Sigma Chemical Co., St. Louis, MO). Fractions in
the void volume containing '251-eta-1 were collected and stored at 4°C. Greater than 90%
ofthe radioactivity in these fractions was precipitable with 10 % TCA and resolved as a single
spot of 65 kD, pI 4.5, after repeat electrophoresis. The 1251-eta-1 obtained by this procedure
had a specific activity of 22.7 ACi/ug.
BindingAssays.
￿
Cells used for binding studies had 90% or greater viability. Binding for
all cell types except RPM was measured as described (15). Briefly, different concentrations
of 1251-eta-1 in 250 ,al of HBSS with 0.1% BSA, 2 MM L-glutamine (binding media) were
added to cells and incubated for 1.5 h at 20°C with gentle rocking. Following reaction, cells
were layered over 1 ml ofa mixture ofsix parts of dioctylpthalate and four parts dibutylpthal-
ate oil (Aldrich Chemical Co., Milwaukee, WI) and centrifuged for 30 min at 40C. Radioac-
tivity in the pellet and supernatant fractions was determinedin a gamma counter (No. 5500B;
Beckman Instruments, Fullerton, CA). Specific binding was defined as the fraction of total
binding that was inhibited in the presence ofa 200-400-fold molar excess of unlabeled eta-1.
In the case of RPM, binding was determined in 96-well tissue culture plates as described
(16). At the end of the 1.5-h incubation, unbound ligand was washed four times with 0.3 ml
of binding medium. Cells were solubilized with 250 p,l of 1% SDS and radioactivity of the
cell lysate was quantitated as above. The 19-mer peptides were synthesized at Multiple Pep-
tide Systems (San Diego, CA) and were 70-80% pure as judged by reverse-phase HPLC.
Histologic Analysis.
￿
Following the subcutaneous injection of eta-1 or control supernatant
into a shaved right axillary region of BALB/c mice, epithelialtissue was removed at intervals
of 3 and 24 h. After fixation in l0olo formalin, tissue was embedded in paraffin, sectioned,
and stained with hematoxylin and eosin or deparaffinized and stained with Giemsa in 10
mM sodium phosphate buffer, pH 7.4. To obtain relative quantitation ofthe number of cells
present in the observed cellular inflammatory infiltrate, cells were enumerated in 20 random
fields surrounding the injection site (histologically representing the dispersion of the dermal
tissue at x 120). The number of leukocytes in each field was determined at x 400 using a
calibrated micrometer grid. The different inflammatory cell types in the infiltrate were as-
sessed using H+E- and Giemsa-stained tissue sections. 200-500 cells at the injection site
were examined to determine the frequency of polymorphonuclear leukocytes (PMN), mac-
rophages, mast cells, lymphocytes, and eosinophils in the cellular infiltrate.
Results
Definition and Purification ofNaturaleta-1 Protein.
￿
We determined the level ofEta-1
RNA expression in a panel of murine T cell lines and clones. As expected from ear-
lier studies, these cell lines did not express Eta-1 under resting conditions as typified
by murine T-cell tumor EL-4 (Fig. 1 A). An exception was a variant of an arsonate-
responsive CD4+ T-cell clone Ar5, termed Ar5v, which constitutively expressed high
levels ofEta-1 RNA before and after stimulation with PMA (Fig. 1, A, B). Analysis
of the secreted products of resting and PMA-stimulated Ar5v cells was performed
by two-dimensional gel electrophoresis under reducing conditions (Fig. 2). After
IIS-metabolic labeling, supernatant fluids of PMA-activated Ar5v cells contained
a major band of65 kD (referred to below as P65) having a pI of 4.5, the approximate
size and charge of recombinant eta-1 (7). P65 was the predominant labeled protein
in stimulated Ar5v supernatant fluids and accounted for -10% ofthe total biosyn-
thetically labeled material. Although resting and PMA-activated Ar5v cells had similar
levels of Eta-1 RNA, the supernatant fluids from the latter contained five- to eight-
fold higher levels ofP65 protein, possibly reflecting a requirement for PMA-dependent
cellular changes required for optimal protein synthesis and/or secretion. Since the1934
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FIGURE 1 .
￿
Expression of Eta-1 in Ar5v cells . A
11P-labeled 1.7-kb Xho I fragment representing
the Eta-1 cDNA insert from pcD-Eta-1 vector was
hybridized onto nitrocellulose filters containing
20 jig oftotalRNA (see Materialsand Methods)
from (A) resting Ar5v and EL-4 cells, and (B)
Ar5v cells stimulated with PMA at 4, 8, and 12
h . Steady-state levels ofTCR-a and IL-2 RNAs
are shown as internal controls to denote constancy
of total RNA blotted for each sample.
predicted eta-1 sequence lacked cysteine residues, we determined the migration of
P65 under nonreducing conditions to rule out the possibility that P65 represented
a reduced component ofa larger S-S bonded molecule . No difference in the migra-
tion ofP65 was noted after electrophoresis in two-dimensional gels under reducing
or nonreducing conditions (not shown) .
Further characterization ofP65 was performed by microsequence analysis of the
FIGURE 2 .
￿
Analysis of proteins produced by Ar-5v T cells by two-dimensional gel electropho-
resis . Biosynthetically labeled proteins in the supernatant fluids of resting Ar5v T-cells (R) and
10 h after activation withPMA (20 ng/ml) (A) . Protein patterns are identical except for the in-
creased expression of an acidic 65-kD (P65) protein together with 55- and32-kD proteins after
activation by PMA . P65 protein is denoted by an arrow. Cells were biosynthetically labeled by
washing with methionine-free DMEM-L-Gln followed by incubation in the same medium sup-
plemented with 100 p,Ci/ml of [35S]methionine (800 Ci/mmol, NewEngland Nuclear) . 10 h later
supernatants were collected and electrophoresed in two dimensions using a modification of the
method of O'Farrell (11) (see Materials and Methods) . The gels were treated with En'hance
(NEN), dried, and exposed for autoradiography . pI scale was determined using amyloglucosi-
dase (pI 3.55), /8-lactoglobulin A (pI 5.13), and myoglobin (pI 6.76, 7.16) as standard proteins .isolated protein (see Materials and Methods). Since the NH2 terminus of P65 was
acetylated, the proteinwassubjectedto trypsin digestion followed by elution of pep-
tide fragments by HPLC. Microsequence analysis of a major peptide fragment in
the HPLC elution profile indicated that this 19 amino acid long sequence was iden-
tical to a fragment of eta-1 representing positions 158-176 (Fig. 3, A, B) and did
not match any other subsequences in the EMBL/GenBank or PIRProtein Sequence
data base. Theseobservations indicate that P65 represents naturally synthesized and
secreted eta-1 protein. Estimation of the amount ofeta-1 proteinin supernatant fluid
of Ar5v cells and in supernatant fluids of pcD-Eta-1 transfected COS7m6 cells ac-
cording to silver staining followed by densitometric scanning indicated that eta-1
expression was around 1-3 /Ag/ml in PMA-Ar5v supernatants. This concentration
was 50-100-fold greater than the concentration of recombinant eta-1 in superna-
tants of transfected COS7m6 cells.
Comparison ofEta-1 Binding to Different Cell Types.
￿
The specificity ofpurified radio-
labeled eta-1 binding to cells was measured in the presence or absence of a 400-fold
molar excess ofunlabeled purified eta-1. Substantial amounts ofeta-1 boundto both
RPM and to the macrophage-like cell line Wehi 3. In both cases, 70-80% of bound
CPM was inhibited by unlabeled eta-1 (Fig. 4). Eta-1 did not specifically bind to
the fibroblast cell line NIH3T3, nor to resting or activatedTh cell clone 03 or Ar5.
Bindingofeta-1 toMacrophages.
￿
To determinethe affinity of eta-1 bindingandnumber
of eta-1 receptors on macrophages, RPM, and Wehi 3 cells were incubated with
80-1,000 pM
12'I-eta-1 for 90 min at 20 GC. RPM or Wehi 3 cell-associated radio-
activity increased until the concentration of
1251-eta-1 was 500 pM, indicating
saturablebinding, and -80% of this bindingwas inhibited by unlabeled eta-1 (Fig.
5). Scatchard analysis of these data indicated -10,500 eta-1 receptors/RPM, each
binding with an apparent Kd of 5.14 x 10 -1° M. Analysis of the Wehi 3 cell line
indicated that these cells had -6,000 eta-1 receptors/cell and that these receptors
had adissociation constant similar to eta-1 receptors on RPM (Kd, 6.54 x 10 -11 M) .
Eta-1 Binds to Macrophages through an RGD Motif.
￿
The predicted amino acid se-
quence of eta-1 includes an RGD-tripeptide subsequence at positions 144-146 (7).
This motifforms a critical part of the cellular binding site on a family of extracel-
lular proteins that are involved in migration and cell-cell interaction (17). We syn-
thesized a 19 amino acid long peptide corresponding to positions 136-154 of eta-1
that contained the RGD tripeptide subsequence (Fig. 3 B). A control peptide con-
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FIGURE 3.
￿
Comparison ofthe amino acid se-
quenceofa P65 peptide with the amino-acid
sequence predicted from Eta-1 cDNA. (A)
Confidence code of sequenced amino acids
from a peptide ofP65 tryptic digest is shown
as high unless otherwise indicated: [ ] prob-
able/reasonable, ( ) possible/low; (B) amino
acid sequence predicted from Eta-1 cDNA is
shown; subsequence matching derived se-
quence of P65 peptide (positions 158-176) is
underlined. The RGD subsequencerepresent-
ing the binding domain of eta-1 is boxed.
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tained two mutations where arginine (R, position 144) and aspartate (D, position
146) were both replaced with leucine (L). Incubation of RPM and Wehi 3 cells with
an excess of theRGD-containing peptidebut not the mutated peptide inhibited 85%
of binding of 1251-eta-1 to RPM and Wehi 3 (Fig. 6).
Effect ofIn ViooAdministration ofeta-1: HistologicAnalysis.
￿
These results, alongwith
previous studies suggesting that eta-1 might affect macrophage responses in vivo
(7), led us to determine whether in vivo inoculation of eta-1 might result in local
accumulation of this cell type. Following intradermal injection of -300 ng of eta-1
into BALB/c mice, a cellular infiltrate was observed at the injection site (as com-
pared with the injection site of a control preparation) at 3 and 24 h (Table I, Fig.
RPM WSHI3 03
￿
Ar5 03.PMA AMPMA NIH3t3
Cell Type
0
FIGURE 4.
￿
Bindingof 1251-eta-1 to different
cell types. 2 x 105 cells were incubated in
0.25 ml of bindingmedium with 1 x 10-9 M
of 1251_eta-1 at 20°C for 1.5 h. Results shown
represent cpmboundat saturation conditions.
Nonspecific binding represents cpmboundin
the presence of a 200-400-fold molarexcess
of unlabeled eta-1. (/) Total binding; ([I)
nonspecific binding.
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FIGURE 5.
￿
Saturation binding curves of radioiodinated eta-1 with (A) RPM and (B) Wehi 3
cells. Cells(2 x 105)were incubatedwith increasing concentrations of 1 51-eta-1 in 250p.l assay
medium for 1.5 hat 20°C. Nonspecific binding(O)wasdetermined in thepresence of a300-400-
fold excess ofunlabeledeta-1.Specificbinding(0) represents thedifference betweentotalbound
(")andnonspecific binding. Inset, Scatchardplot of thesame data. (B)boundeta-1, (F)free eta-1.
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FIGURE 6.
￿
AnRGD peptide inhibits eta-1 bindingto mac-
rophages . 2 x 105 cells were preincubated with 0.48 ,aM
ofRGD 19-mer orLGL 19-mer peptides along with0.4nM
of 125j-eta-1 for 1.5 h at 20°C . Specific binding of eta-1 is
shown. (®) 1251-eta-1 ; (E)) 1251-eta-1 + RGD19mer; (" )
1251-eta-1 + LGL19m-
7, A, B) . Thenumbersofinflammatory cells were elevated as early as 3h after injec-
tion of eta-1 and at 24 h showed a 10-fold increase compared with control injection
sites (Table I) . The majority of cells in the cellular infiltrate were macrophages (Fig.
7, C, D) and thenumber of these cells 24h after eta-1 injection was N25-fold greater
than in control injection sites . A significant, albeit less pronounced, elevation was
also noted in the numbers of PMN, which increased fivefold after eta-1 injection .
It was unlikely that the histologic reactions associated with eta-1 inoculation reflected
the effects ofcontaminantendotoxin since the preparation ofeta-1 used in these studies
TABLE I
Histologic Analysis of the Cellular Infiltrate following
Subcutaneous Injection of Eta-1
" Mean number of cells/mm 2 obtained from 20 random fields surrounding the
injection site after staining with hematoxylin and eosin . Each group represents
the results from three individual mice and the data shown represent one of
three similar experiments .
t Differential analysis ofthe cells present in the inflammatory infiltrate after tis-
sue sections were stained with hematoxylin + eosin or Giemsa to delineate
nuclear configuration . The absolute numbers ofeach cell type/mm2 are shown
below .
1937
Number of
cells/mm2 "
Mean SE PMN
Percent of cells/mm2 2
MAC LYM MAST EOS
Control (3 h) 19.4 1 .1 61 .1 29 .1 0.6 8.3 0.6
eta-1 (3 h) 69.8 5.2 42.4 44 .1 1 .2 11 .6 0.8
Control (24 h) 10 .1 1.8 71 .0 15 .8 3 .7 7 .4 1 .8
eta-1 (24 h) 99.7 5 .2 35 .2 56.8 1 .9 5 .0 0 .5
Number of cells/mm 2
Total PMN MAC LYM MAST EOS
Control (24 h) 10 7 2 0 1 0
eta-1 (24 h) 100 35 56 2 5 11938
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FIGURE 7 .
￿
Histopathological analysis of cellular response following subcutaneous administra-
tion of eta-1 . (A) 24 h following the subcutaneous injection of control supernatant, there was
no recognizable inflammatory infiltrate into the local dermal tissue . Individual leukocytes were
noted either in small endothelial lined vascular spaces or in the dermal loose connective tissue
(x200) . Arrows show leukocytes . (HF) hair follicle ; (EVS) endothelial lined vascular spaces . (B)
24 h following the subcutaneous injection of 300 ng of eta-1, there was a dense inflammatory
infiltrate of mononuclear cells and polymorphonuclear leukocytes within the interstices of loose
connective tissue and adipocytes (x200) . Arrows show inflammatory cells (IC) . (C) Higher
magnification (x400) of an endothelial-lined vascular space located at the subcutaneous injec-
tion site of control material showsa paucity of inflammatory cells in the loose connective tissue
surrounding ablood vessel . (RBC)red blood cells ; (IC) inflammatory cells ; (LCT) loose connec-SINGH ET AL.
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contained <0.1 ng/g endotoxin, the lower limit ofdetection using a Limulus lysate
assay.
Discussion
We have previously described a murine cDNA, termed Eta-1, that is strongly ex-
pressed after activation ofT cells (7). TheEta-1 gene maps totheRiclocus on chro-
mosome 5, which confers resistance to infection by an obligate intracellular bacte-
rium and encodes a secreted protein that includes an RGD-containing cell-binding
domain of the extracellular matrix protein similar to that of fibronectin (7, 17).
Previous studies of Eta-1 have suggested that although it is secreted by T cells,
it confers resistance to bacterial infection in vivo by affecting the ability of macro-
phages to migrate to the site of infection and/or to ingest and destroy bacteria (7).
We thereforeattemptedto determine whether macrophagesexpressed eta-1 receptors.
Although recombinantEta-1 hasbeen expressedin COScells(7), the levels ofrecom-
binant eta-1 expression in transfectant cell supernatant fluids (picograms to nano-
grams/milliliter) hindered attempts at purification ofthe eta-1 protein for binding
and functional studies. We screened avarietyofTcell lines toidentify a cell producing
high levels of natural eta-1. This resulted in purification of eta-1 from supernatant
fluids ofa murine CD4+ Th cell clone in sufficient amounts for studies of its inter-
action with macrophages in vitro and its ability to induce a cellular inflammatory
response in vivo.
We used the radioiodinated eta-1 protein purified by extraction from polyacryl-
amide gels for cell bindingstudies. Elution ofproteins from acrylamide gels proved
to be a rapid method forobtaininga homogenous preparation ofeta-1 that retained
binding activity invitro andmacrophage recruitmentactivity in vivo. This approach
has been used previously for preparingbiologically active IFN-y (18), IL-1 (19), and
MDGF (20).
Eta-1 bound toperitoneal macrophages explantedfrom mice andtothemacrophage-
like cellline Wehi 3, but notto the fibroblast cell line NIH3T3 nor totwo Thclones.
Bindingto macrophageswas specific, saturable, and displayedhigh affinity kinetics.
The observed Kd of eta-1 was 5 x 10-11 M for RPM and Wehi 3 cells and the
numberofeta-1 receptors was _104/cell, about the same as that detected for IFN-y
(21). The linear Scatchard plot thatdescribes bindingkinetics indicates a noncooper-
ative interactionbetween eta-1 and its receptor on macrophages, suggesting thepres-
ence of a single class ofeta-1 receptor for this cell type. By contrast, macrophages
appear to expressboth low andhighaffinity forms ofIFN-yreceptor (22). The affinity
of the eta-1 receptor described in this report is similar to the high affinity form of
theIFN-yreceptor andabout oneloghigher thanthe lowaffinity gamma-IFNreceptor
on macrophages (21, 22). We have not determined whether other leukocytes that
participatein inflammatory responses such asmastcells and PMN also expresseta-1
receptors. The increase in the frequency ofthe latter cell type in cellular infiltrates
followingeta-1 administration in vivo suggests that this cell type may also beareta-1
tive tissue. (D) The injection site of eta-1 shows substantial margination of inflammatory cells
exiting from the vascular lined spaces. These cells are also noted within the vessel (x 400). (M)
mononuclearcells; (P) polymorphonuclearleukocytes; (MAR) margination; (RBC) red blood cells.1940
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receptors or that the interaction between eta-1 and macrophages may result in the
elaboration of material that results in an accumulation ofPMN.
Eta-1 includes an Arg-Gly-Asp (RGD) subsequence that marks a family of ex-
tracellular matrix moleculesthat induce changes in cellular motility and/or differen-
tiation (7, 17) . In most cases, this subsequence forms a critical part of the protein's
binding site to cell surface receptors. Although the positive and negative charges
of theArgand Asp residues arenecessary forbinding, additional structural proper-
ties of flanking sequences are required to ensure cell binding (23, 24) . We therefore
synthesized a 19-mer peptide that represented theRGD domain of eta-1 . This pep-
tide, but not a peptide with a mutated RGD site (Arg-Gly-Asp to Leu-Gly-Leu),
inhibited eta-1 binding to macrophages, suggesting that the RGD domain of eta-1
is essential to its binding to macrophages . Moreover, preliminary studies indicate
that theRGD peptide, butnot amutated peptide, inhibit the induction ofacellular
infiltrate by eta-1 in vivo, supporting the view that this portion of eta-1 represents
acritical site allowing physiological interaction of eta-1 with inflammatory cells . We
do notknow whether the in vivo effects of eta-1 reflect increasedmacrophage migra-
tion out of thevascular spaceinto surrounding tissue or in situ proliferation of tissue
macrophages. We favor the former possibility because of the prominence of ex-
travasating macrophageslocated at the marginsof smallvessels on histologic exami-
nation . According to this hypothesis, macrophages making contact with eta-1 at the
spaces between endothelial cells and epimyoepithelial cellsmigrateoutofblood vessels
into extravascular tissue across an eta-1 gradient . Further studies of potential
chemotactic activity ofeta-1 in vitroand the role of the RGD-containing subsequence
of the molecule are required to test this idea .
Macrophages express severalbiologically active receptors, includingMac-1, LFA-
1, and p150,95, which are structurally similar to the fibronectin receptor, and may
in principle, bind to extracellular molecules that express RGD-bindingdomains (25).
Attachment offibronectin to macrophagesviaanRGD-site can result in an increase
in receptors for the Fc portion of Ig and for C3b proteins (26, 27). Studies are in
progress to determine the in vitro effects of eta-1 on macrophage physiology and
to define the surface structure(s) that function as the macrophage eta-1 receptor.
Summary
The Eta-1 gene specifies a secreted product of activatedT cells and is associated
with genetic resistance to infectionby an obligate intracellularbacterium . Previous
studies have suggested that eta-1 might affect the ability ofmacrophages to migrate
to the site ofbacterial infection and/or to inhibit intracellular bacterial growth .We
therefore examined the interaction of eta-1 with macrophages in vitro and in vivo.
We find that macrophages express ti 10 9 eta-1 receptors/cell and each receptor has
a Kd of -5 x 10-1°M . The subsequence of eta-1 containing an RGD motif is re-
quired for binding because a synthetic peptide containing the eta-1 RGD domain
inhibited protein attachment to macrophages.We also found that subcutaneous in-
oculation of mice with eta-1 resulted in a cellular infiltrate comprised primarily of
macrophages . We proposethat theinteraction between eta-1 and itsreceptor on mac-
rophages results in a change in macrophage physiology resulting in accumulation
of these cells at extravascular sites .SINGH ET AL.
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